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Background: The identification of acid mucopolysaccharide by the liquid chromatography/tandem mass spectrometry
method (LC-MS/MS) of the predominant disaccharide units of glycosaminoglycans (GAGs) (chondroitin sulfate, CS;
dermatan sulfate, DS; heparan sulfate, HS) after methanolysis is validated and applicable for mucopolysaccharidosis (MPS)
type determination.
Methods: A total of 76 urine samples were collected and analyzed, from nine MPS I patients, 13 MPS II patients, seven
MPS III patients, eight MPS VI patients, and 39 normal controls. Urinary GAG was first precipitated by the Alcian blue
method followed by a treatment of 3 N HCl methanol. The protonated species of the methylated disaccharide products
were detected by using a multiple reaction monitoring experiment. Internal standards, [2H6] CS, [
2H6] DS and [
2H6] HS,
were prepared in-house by deuteriomethanolysis of CS, DS and HS.
Results: One particular disaccharide for each GAG was selected, in which the parent ion and its daughter ion after
collision were m/z 426.1→ 236.2 for DS (m/z 432→ 239 for dimers derived from [2H6] CS and [
2H6] DS) and m/z
384.2→ 161.9 for HS (m/z 390.4→ 162.5 for the [2H6] HS dimer). The quantities of DS and HS were determined, which
varied from one MPS type to the other. The results can be used to evaluate the severity of MPS subgroups, as well as
urinary GAG amelioration at follow-up after enzyme replacement therapy (ERT).
Conclusions: The modified LC–MS/MS method for MPS type determination is specific, sensitive, validated, accurate, and
applicable for simultaneous quantifications of urinary DS and HS. This method can help to make correct diagnosis of
MPS patients and evaluate the effectiveness of ERT.
Keywords: Enzyme replacement therapy, Glycosaminoglycans, Liquid chromatography/tandem mass spectrometry,
Methanolysis, MucopolysaccharidosisIntroduction
The mucopolysaccharidoses (MPS), known as a group of
lysosomal storage disorders, are caused by the deficiency
of specific enzymes that catalyze the stepwise degradation
of glycosaminoglycans (GAGs; mucopolysaccharides).
There are at least 11 known enzymes involved in the* Correspondence: zsplin14@gmail.com
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unless otherwise stated.catabolism of dermatan sulfate (DS), heparan sulfate (HS),
keratan sulfate (KS), chondroitin sulfate (CS), and hyalur-
onic acid (HA) [1-3]. Any enzyme deficiency will block
the GAG degradation, which results in GAG macromole-
cules with a specific carbohydrate or sulfated carbohydrate
residue accumulating in cells, causing severe dysfunction
[1-4]. The clinical manifestations of MPS are chronic and
progressive. The severity and prognosis vary from one
type to another with a wide spectrum of clinical severity.
MPS patients present with many distinct clinical features,
including organomegaly, developmental delay, dysmorphicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and growth retardation. In addition, hearing [5], vision
(mostly with corneal clouding), pulmonary and cardiovas-
cular function [6,7], bone mineral density [8], and joint
mobility are also affected. The MPS clinical features
may present from birth to late childhood or even in
early adulthood, depending on the severity of the MPS
type. Death from respiratory or cardiac failure and respira-
tory infections usually occurs before the age of 10 years
in severe phenotypes [1-4,9].
An accurate diagnosis is achieved generally by three
sequential tests: the quantification of urinary GAG,
two-dimensional electrophoresis (2-D EP) qualitative
analysis, and leukocyte enzyme activity assay [10-12].
Urinary GAG quantitative analysis can provide a screen
for MPS diagnosis, but cannot be used to identify a
specific MPS disease. A 2-D EP is the most common
and feasible method used for specific MPS disease.
Nevertheless, this method is time-consuming and requires
more than two days to complete a test. Moreover, the
interpretation is difficult and subjective, which can make
the diagnosis unreliable. Particularly, the interpretation
of the 2-D EP pattern is ambiguous due to the affected
GAGs being similar in MPS I, II, and VI. Based on the
limitations of MPS first-line screening methods, the
establishment of an advanced liquid chromatography/
tandem mass spectrometry method (LC-MS/MS) for MPS
subgroup determination is valuable and important.
The polysaccharide chains are elongated by the sequen-
tial addition of alternating acidic and amino sugars,
donated by their UDP-derivatives. Amino sugars are
essential components of GAGs, glycoproteins, and gly-
colipids. Members of the GAG family vary in the type
of hexosamine, hexose or hexuronic acid unit they
contain (e.g. glucuronic acid, iduronic acid, galactose,
galactosamine, glucosamine) [13]. The specific GAGs
of physiological significance are DS, CS, HS, KS, and
HA. Although each of these GAGs has a predominant
disaccharide component, heterogeneity does exist in
the sugars presented in the make-up of any given class
of GAG. In this study, the identification of acid MPS
by the modified LC-MS/MS method of the predo-
minant disaccharide component of GAGs after metha-
nolysis [14-18] is proposed and validated for MPS type
determination [19,20].
Materials and methods
The LC-MS/MS method for GAG disaccharide analysis
was modified according to the literature reported by
Auray-Blais et al. [19]. For GAG disaccharide LC-MS/MS
analysis, a multiple reaction monitoring (MRM) experiment
giving a precursor molecular ion (Q1) and a respective
fragment ion (Q3) was normally applied. The instrument
was operated in a positive-ion ([M +H]+) mode. Thequadrupoles, Q1 and Q3, were tuned with unit resolution,
and the MS conditions were optimized for maximum
signal intensity. The LC-MS/MS analysis was performed
on a 4000 QTRAP LC-MS/MS system (AB Sciex, Foster
City, CA, USA) equipped with a TurboIonSpray (electro-
spray ionization; ESI), and Agilent 1260 Infinity HPLC
pump and autosampler (Agilent Technologies, Santa Clara,
CA, USA). The experimental parameters were set and
are clearly described in the following section. Data were
acquired and processed using Analyst 1.5.2™ software
(AB Sciex). Calibrations of GAG standards and internal
standards were performed with every batch of samples.
MPS patient details and normal control
A total of 76 urine samples were collected and analyzed
from nine MPS I patients, 13 MPS II patients, seven
MPS III patients, eight MPS VI patients, and 39 normal
controls. MPS I phenotypes comprised five MPS I-Hurler/
Scheie (H/S) and four MPS I-S patients according to
their progressive central nervous system and the severity
of somatic manifestations. They have received enzyme
replace therapy (ERT) in a varied duration, from one
month to 8.8 years, and the ages of ERT initiation were
from 0.7 to 34.9 years old. In those, two patients expired
due to respiratory infection and complications. For MPS
II phenotypes, eight severe and five mild forms were
inclusive in this study. All 13 patients have received
ERT and the duration of receiving ERT was from 1.3 to
7.3 years. The ages of ERT initiation were varied, from
4.5 to 18.3 years old. The seven MPS III patients were
identified as one IIIA, three IIIB, and three IIIC and all
patients were confirmed by leukocyte enzymatic assays.
No MPS VI phenotypes were further classified. Soft
tissue and skeletal disease presented in MPS VI patients,
but without central nervous system (CNS) involvement.
These patients have received ERT from 3 to 10.3 years,
and the ages of ERT initiation were from 4.4 to
21.2 years old. Normal controls (n = 39) were chosen
from out-patient department, and informed consent was
obtained from all normal population and MPS patients.
The study was approved by the ethics committee of
Mackay Memorial Hospital, Taipei, Taiwan.
GAG precipitation and methanolysis
Urine samples (approximate 10 mL) were collected in a
sterile urine container (polyethylene; Nalge Nunc Inter-
national, USA). The method of GAG precipitation was
described previously [10-12]. GAGs were first precipitated
from urine using the Alcian blue (AB) reagent containing
sodium acetate. Then, sodium chloride and methanol
were used to dissolve MPS-AB complex. Sequentially,
sodium carbonate was added to dissociate the MPS com-
plex and AB. Finally, ethanol was used to reprecipitate
MPS. After evaporated to dryness, the precipitate was
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in mg/L, and the supernatant was subjected to methanoly-
sis based on the method reported by Chambers RE et al.
[21]. The GAGs were then degraded to uronic acid-N-
acetylhexosamine dimers [10-12].
Calibration and sample preparations
Calibrators including CS, DS, and HS were purchased
from Sigma Co. (Saint Louis, MO, USA). The stock
solution of individual standard was prepared in a con-
centration of 1 mg/mL. The calibration curve was made by
adding five different volumes for each GAG standard, and
the final concentrations of five mixed working standards
were 12.5, 25, 50, 100, and 200 μg/mL for DS; 6.25, 12.5,
25, 50, and 100 μg/mL for CS; 3.125, 6.25, 12.5, 25, and
50 μg/mL for HS, respectively. The five prepared GAG
working standard mixtures (70 μL) and the precipitated
GAG sample (2 μL) were added into tubes separately,
and then, all the tubes were dried by nitrogen gas using
the following methanolysis processes. The methanolysis
was performed by adding 3 N HCl in methanol (200 μL)
and 2, 2-dimethoxypropane (10 μL). After drying under
nitrogen, acetonitrite (100 μL) and a mixture of GAG
internal standards (100 μL) were added, and dried again.
Reconstitution of the standards and samples was per-
formed with 100 μL ammonium acetate (NH4OAc;
10 mM). The reconstituted fluids were filtrated and cen-
trifuged by using a 3 kDa Amicon filter in 12,000 rpm
for 30 minutes. After this, the filtrates were ready for
LC-MS/MS analysis.
Internal standard preparations
The internal standards including [2H6] DS, [
2H6] CS,
and [2H6] HS, were derived in-house from deuterio-
methanolysis of GAG standards comprising DS, CS, and
HS, according to the method reported by Zhang et al.
[20]. The formation of 2HCl in C2H3O
2H (2 mol/L) was
first performed by adding a drop of acetyl chloride
(CH3COCl) into deutrioacetate (C
2H3O
2H) on ice. The
stock solution of individual GAG standard (300 μL) was
added into a tube separately, and dried by nitrogen for
15 minutes. After drying, 2HCl in C2H3O
2H (300 μL) was
added and incubated in 65°C for 75 minutes. After being
dried by nitrogen for about five minutes, deionized water
(2 mL) was added and stored in ice (−20°C). A mixture of
GAG internal standards with the same volumes of [2H6]
DS, [2H6] CS, and [
2H6] HS was ready for LC-MS/MS
analysis. The GAG internal standard mixture was stable in
4°C for seven days.
Experimental parameters of LC-MS/MS analysis
The LC-MS/MS analysis was performed on a 4000
QTRAP triple-quadrupole MS system equipped with a
TurboIonSpray, and Agilent 1260 Infinity HPLC pumpand autosampler. The 3-μm Atlantis dC18 column (3.0 ×
50 mm) was purchased from Waters Corporation
(Milford, MA, USA). The mobile phase A consisted of
5 mM NH4OAc (pH 5.5) in deionized water containing
0.1% formic acid and the mobile phase B consisted of
5 mM NH4OAc (pH 5.5) in 100% methanol, delivered
in a gradient elution starting at 100% water and ending
at 100% water at a flow rate of 450 μL/min. The
injection volume was 5 μL, and the total run time was
6.5 minutes. The instrument was operated in the
positive-ion mode. The experimental parameters were
set as followed: curtain gas at 10 psi, CAD set at
medium, IonSpray voltage at 5500 V, temperature at
450°C, Gas 1 at 50 psi, and Gas 2 at 60 psi. Nitrogen
was used for the curtain gas, Gas 1, Gas 2, and collision
gas. Data were acquired and processed using Analyst
1.5.2™ software (AB Sciex).
The calibration curve was made by plotting the
standards with six concentrations including 0 μg/mL
(X-axis) and their integrated areas (Y-axis) after MS/MS
measurements. The linear range was set from 12.5 to
200 μg/mL for DS; 6.25 to 100 μg/mL for CS; and 3.125
to 50 μg/mL for HS. The “linear through zero” regres-
sion was excellent (y = 9.35e + 0.004×; r = 0.9994). The
within-run and between-run precisions of the assay
were determined by assay of three samples in triplicate
over a period of three days. In this study, the triplicate
results in low (10 μg/mL for DS; 2.5 μg/mL for HS),
medium (50 μg/mL for DS; 20 μg/mL for HS), and high
levels (150 μg/mL for DS; 40 μg/mL for HS) from three
runs were used to estimate within-run and between-run
precisions.Results
Transition mass-to-charge ratio (m/z) of GAG standards
and internal standards
One particular disaccharide for each GAG was se-
lected, in which the parent ion and its daughter ion
after collision were m/z 426.1→ 236.2 for DS (reten-
tion time = 3.30 ± 0.06 minutes) and CS (retention
time = 3.75 ± 0.11 minutes), and m/z 384.2→ 161.9 for
HS (retention time = 3.43 ± 0.09 minutes). The mass
spectrum of the deuteriomethanolysis product of DS
showed the incorporation of +6 atoms of deuterium,
the same as that of HS. The protonated molecular
ion was the transition m/z 432→ 239 for [2H6] CS
and [2H6] DS dimers (retention time = 3.71 ± 0.09
minutes and 3.26 ± 0.05 minutes, respectively), as well
as the molecular ion transition m/z 390.2→ 168
for the [2H6] HS dimer (retention time = 3.39 ± 0.06 mi-
nutes). Quantifications were achieved using peak areas
that were processed using Analyst 1.5.2™ software (AB
Sciex).
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spectrometry assay
The within-run and between-run precisions were deter-
mined by an assay of total 18 samples in low, medium,
and high concentrations of DS and HS using the method
described earlier. All 18 samples were run in triplicate
for within-run analysis, and a duplicate analysis of each
sample (n = 18) was performed on three different days
sequentially. The average within-run and between-run
CV was 9.7% (low conc.), 6.4% (medium conc.), and 5.9%
(high conc.), as well as 11.8%, 7.6%, and 9.3%, respectively.
The analytical recovery was also investigated by spiked
standards with known concentrations of DS and HS
(20 μg/mL for each standard) into pooled normal urine
samples as in the precision studies. The recoveries of this
LC-MS/MS assay were 94.3% for DS (ranging from 91.9%
to 97.6%), and 95.1% for HS (ranging from 92.3% to
98.4%). The linearity study of this method was carried out
with concentrations ranging from 12.5 to 200 μg/mL for
DS, and 3.125 to 50 μg/mL for HS. Each concentration
was performed in triplicate. Linearity of DS and HS was
calculated individually and the correlation coefficients (r)
were 0.9914 for DS and 0.9935 for HS, respectively.
Overall distributions of DS and HS in MPS patients and
normal controls
In this study, a total of 76 urine samples were collected
and analyzed. As shown in Figure 1, normal samples
could be easily distinguished from MPS patients based
on the cut-off point (about 10 μg/mL) determined fromFigure 1 The overall quantitations of DS and HS in urine of different
7 for MPS III, 8 for MPS VI, and 39 for normal controls).overall urinary DS and HS measurements. In the control
group, the only GAG that could be identified in urine
was CS; there was no or very little DS and HS. In the
MPS I and II patients, there was primarily an accumula-
tion of both DS and HS, resulting in enhanced excretion
in urine. In the MPS III patients, the affected GAG was
HS, and in the MPS VI patients, the affected GAG was
primarily DS.The mass spectrum of different MPS types and normal
controls
The mass spectrums of the normal control and each
MPS type are illustrated in Figure 2 (A-F). The major
urinary GAG found in normal control was CS, and with
very small amounts of DS and HS, but not significant
(Figure 2A). The only predominant similarity of affected
GAGs among MPS I, II, and VI patients was DS; HS was
found particularly in MPS I and II patients. The results
showed a significant elevation of DS excreted in the urine
of MPS I, II, and VI patients; levels of HS varied among
them. Elevated excretion of HS was observed most signifi-
cantly in the severe form of MPS II, and then, in the mild
forms of MPS II, MPS I and MPS VI patients in decreas-
ing order of elevations. The quantity of urinary HS in
MPS VI patients was very little amount, and almost
equivalent to that of the normal value. For those with
MPS III, HS was the principal GAG that was grossly accu-
mulated and excreted in urine, and showed a distinct HS






Figure 2 Mass spectrum of DS and HS in urine, as well as the internal standards of different MPS phenotypes and normal controls.
(A) Normal control; (B) MPS I- Scheie; (C) mild form of MPS II; (D) severe form of MPS II; (E) MPS IIIB; and (F) MPS VI. *Same pairs of transition
mass-to-charge ratio for [2H6] CS and [
2H6] DS dimers (m/z 432→ 239), and the retention time (minutes) for [
2H6] CS and [
2H6] DS dimers is
3.71 ± 0.09 and 3.26 ± 0.05 minutes, respectively.
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types and normal controls
The average concentrations (in μg/mL) of urinary DS
and HS found in different MPS types and the normal
controls were determined. The majority of urinary GAG
found in normal control was CS (71.9 ± 46.6 μg/mL)
with very little DS and HS (less than 1.68 ± 1.01 and
3.88 ± 2.16 μg/mL, respectively). In MPS I patients, DS
and HS were simultaneously detected and were shown
to be significantly elevated when comparing with normal
control (p < 0.005 for DS; p < 0.001 for HS), and the
concentrations were 276.9 ± 301.0 and 7.3 ± 8.7 μg/mL,respectively. When comparing the quantities of DS and
HS in MPS I and II patients, the urinary HS in the
severe form of MPS II was significantly greater than that
of MPS I and the mild form of MPS II (824.0 vs. 7.3 and
22.9 μg/mL; p < 0.01), and the DS was slightly lower than
that found in MPS I and the mild form of MPS II patients
(164.6 vs. 276.9 and 258.6 μg/mL; p < 0.05) (Figures 3A
and B). HS was predominant in the urine of MPS III
patients, with an approximate average amount of
8901.4 μg/mL, which was thousands of times higher
than the amounts seen in the normal control group.
The differences were all significant when comparing
Figure 3 The comparison of affected GAGs showed significant differences among different MPS types (n = 9 for MPS I; n = 5 for mild
form of MPS II, and n = 8 for severe form of MPS II; n = 7 for MPS III; and n = 8 for MPS VI), and normal control (presented in log scale).
Urinary DS (A) and HS (B) concentrations in average (μg/mL) detected in different MPS types and normal controls.
Chuang et al. Orphanet Journal of Rare Diseases 2014, 9:135 Page 6 of 10
http://www.ojrd.com/content/9/1/135within the different MPS types (p < 0.01). A very small
amount of DS (0.73 μg/mL) was found in MPS III
patients. The predominantly affected GAG in MPS VI
patients was DS, which was seen to be moderately ele-
vated, approximately 105.5 μg/mL on average, and a
relatively little amount of HS (1.26 μg/mL) was observed.
No significant difference was found when comparing DS
values between the severe form of MPS II and MPS VI.
This was a reliable indicator to discriminate MPS VI from
MPS I and II (p < 0.01 and p < 0.05). The quantificationsof DS and HS in different MPS types are compared and
shown in Figures 3A and B (log scale).
Evaluation of the effectiveness of enzyme replacement
therapy (ERT) in MPS patients
To evaluate the amelioration of MPS patients receiving
ERT, the reduction of urinary GAG (DMB/creatinine
ratio) and particular disaccharide units of the affected
GAGs were measured for three successive years. The
average reductions of urinary GAGs after ERT in MPS I
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In the first year, the reductions were 62.0%, 71.5%, and
61.9%, respectively. In the second year, they were 72.5%,Figure 4 Evaluations of the effectiveness of ERT in MPS patients. The
significant (A); the reduction of DS and HS in patients with MPS I- Scheie (85.5% and 77.9%. In the third year, they were 71.9%, 88.1%
and 87.6% (See Figure 4A). For MPS I-S and the mild
form of MPS II patients, the reductions of DS and HSreduction of urinary GAGs after ERT in MPS I, II, and VI patients was
B), and the mild form of MPS II (C) patients after ERT was notable.
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54.7%, as well as 31.5% and 76.9% in the first six months;
90.8% and 98.4%, as well as 96.4% and 94.3% in the first
year; and a greater than 97.1% reduction for both in the
second and the third years (Figures 4B and C).
Discussion
The aim of this research project is to develop a LC-MS/
MS method for MPS type determination instead of the
conventional 2-D EP method. The data showed that the
LC-MS/MS method was highly specific and highly sensitive
to discriminate well among DS, HS, and CS, even with a
trace of GAG content in the urine sample. It is encouraging
to see that the results of this study are successful and can
be used to distinguish one MPS type from the others.
Two main merits of our method that differ from the
method reported by Auray-Blais et al. are sample itself
and the addition of internal standards. According to the
method previously reported by Auray-Blais et al., a small
amount of the urine sample is directly methanolyzed
without undertaking GAG precipitation. By doing it this
way, a black sticky analyte is formed, which cannot be
successfully introduced into LC-MS/MS for further
analysis as it obstructs the HPLC flow and column. By
performing the GAG precipitation, the feasibility of CS,
DS, or HS detections in the urine sample could be
significantly enhanced. Without a doubt, the addition of
stable-radioisotope internal standards (IS) is another
merit of our method modification. Combined with the
addition of internal standards, the eluted positions of CS,
DS, or HS can be precisely identified. In addition, the rela-
tive concentrations of CS, DS, and HS in the urine sample
can be obtained by integrating the peak areas between the
individual GAG and that of internal standard with known
concentration. The internal standard can also be used as a
quality assurance in LC-MS/MS analysis.
Based on the results detected by LC-MS/MS method,
the quantities of affected GAGs are distinctive for MPS
type determinations. The results are fully matched with
those examined by 2-D EP method, and correspond
well with the leukocyte enzymatic assay. The LC-MS/MS
method used for MPS type determination has many
advantages, including high sensitivity, high specificity, high
throughput, high reliability, and analytic automation. The
highly sensitive of LC-MS/MS method was achieved
and the lower limit of quantitation (LLOQ) was less
than 0.06 μg and 0.065 μg with 100 μL urine for DS and
HS, respectively. The high specificity of MRM detection
allowed specific detection of DS and HS, in which the
parent ion and its daughter ion after collision were m/z
426.1→ 236.2 for DS and m/z 384.2→ 161.9 for HS.
The LC-MS/MS method can also be used for MPS
subgroup classifications, particularly for MPS II. In this
application, the concentration of HS is the key factorused to distinguish the mild form of MPS II from the
severe form. The results obtained in this study showed
that the concentrations of HS detected from the samples
of the severe form MPS II patients were significantly
higher than those of the mild form MPS II patients. The
increase was over 35 times greater (824.0 vs. 22.9 μg/
mL). The results also showed that the concentrations of
DS were varied among MPS I, MPS II, and MPS VI. The
quantities of DS detected from MPS VI patients was
significantly lower than those with MPS I and the mild
form MPS II patients; but was equivalent to those of
severe form MPS II patients. As very little or no HS was
seen in the samples from MPS VI patients, and this can
be used as a marker.
Disease-specific treatments to replace specific enzyme
activity include ERT for the non-neurologic manifesta-
tions of MPS patients [22-31], and bone marrow as well
as hematopoietic stem cell transplantations for MPS I,
II, IV, and VI patients [32,33]. de Ru et al. reported that
ERT can result in good clearance of GAGs from many
tissues and can significantly ameliorate several symptoms
[29]. The effectiveness of ERT for patients with MPS I, II,
and VI is significant. In general, the improvement of
symptoms or physiological activities is one major indicator
used to evaluate the effectiveness of ERT, as is, the
clearance of GAGs from urine. Notably, the DMB ratio
significantly ameliorated and declined to 55% to 65% of
the original value when MPS patients had received ERT
for more than three to six months. The DMB ratio can give
useful information to evaluate the effectiveness of ERT;
however, it cannot show which GAG can be degraded well
after ERT. HS is mainly found in the central nervous
system and it accumulates in the brain if it cannot be
broken down due deficient or missing enzymes. By using
the LC-MS/MS method, this study showed that the con-
centrations of both DS and HS are reduced significantly
when comparing the predominant disaccharide units in
MPS I and II patients before and after ERT. The results
demonstrate that the reductions of DS and HS after ERT
are substantial, and the value of predominate disaccharide
unit detections by using LC-MS/MS method is suitable
for routine purposes and useful in evaluating the MPS
progressive conditions.
Conclusions
The LC-MS/MS method used for MPS type determination
is specific, sensitive, validated, reproducible, accurate and
applicable for simultaneous quantification of urinary DS
and HS. By using this method, MPS can be properly
diagnosed. As well, this method can be used to evaluate
the effectiveness of follow-up therapy.
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